Bupropion Coadministration for Dextromethorphan Plasma Level Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods fail to effectively increase dextromethorphan plasma levels and reduce adverse effects in extensive metabolizers, leading to inefficiencies and adverse events in dextromethorphan treatment.
Innovation Solution
Co-administration of bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion, or their prodrugs, with dextromethorphan to inhibit metabolism and increase plasma levels, thereby reducing dextrorphan levels and adverse events.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dextromethorphan is administered to extensive metabolizers, then cough suppression is achieved, but plasma levels are insufficient and adverse events occur
Solution Approach 1:
Bupropion is introduced as an intermediary substance that modulates dextromethorphan metabolism. It acts as a selective inhibitor of dextromethorphan 2-hydroxylation, thereby increasing dextromethorphan plasma levels and extending its metabolic lifetime without causing significant adverse events when used at controlled doses (e.g., 150 mg/day).
Solution Approach 2:
The patent changes the pharmacokinetic parameters of dextromethorphan by co-administering bupropion, which increases dextromethorphan AUC (area under the curve) and Cmax (maximum concentration) while extending the metabolic lifetime from approximately 2 hours to 4-6 hours, thereby optimizing therapeutic efficacy and reducing adverse events.
2Reliability
If dextromethorphan plasma levels are increased, then therapeutic efficacy is improved, but adverse events increase
Solution Approach 1:
Bupropion serves as a selective metabolic modulator that increases dextromethorphan plasma levels through specific inhibition of 2-hydroxylation, rather than non-selective inhibition that would cause excessive accumulation and adverse events. This targeted approach allows plasma level optimization while maintaining safety.
Solution Approach 2:
The patent establishes a feedback mechanism where bupropion dose is controlled (e.g., 150 mg/day) to achieve optimal dextromethorphan plasma levels. The combination is monitored for efficacy and adverse events, allowing dose adjustment to maintain therapeutic window and prevent toxicity.
3Duration of action of stationary object
If dextromethorphan is administered multiple times, then therapeutic effect is maintained, but dextrorphan accumulation occurs
Solution Approach 1:
Bupropion acts as a selective inhibitor of dextromethorphan metabolism, thereby reducing the formation of dextrorphan (the active metabolite) during repeated dosing. This allows maintenance of therapeutic effect through multiple administrations without significant dextrorphan accumulation, as bupropion specifically targets the metabolic pathway that produces dextrorphan.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances dextromethorphan plasma levels and metabolic lifetime, decreases dextrorphan plasma levels over multiple days, and reduces adverse events, improving therapeutic efficacy and safety.
Implementation Method 1
Co-administration of bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion, or their prodrugs, with dextromethorphan to inhibit metabolism and increase plasma levels
Implementation Method 2
thereby reducing dextrorphan levels and adverse events
Data Source
AI summary
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.